OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Gaps Persist in Understanding the Fundamentals of Informed Consent

Jul 14, 2021
Maurie Markman, MD
Publication
Article
Oncology Live®Vol. 22/No. 14
Volume 22
Issue 14

In Partnership With:

Within the hierarchy of clinical trials, phase 3 randomized studies remain the gold standard, though some argue that appropriately designed meta-analysis of multiple studies provides even more definitive and meaningful insight.

Maurie Markman, MD

Maurie Markman, MD

This has been an interesting and complex year in the realm of clinical trials. The results of multiple COVID-19 studies provide a remarkably powerful testimony to support well-designed, well-conducted trials and highlight the importance of interpreted investigative studies in optimizing the health of our society. Within the hierarchy of clinical trials, phase 3 randomized studies remain the gold standard, though some argue that appropriately designed meta-analysis of multiple studies provides even more definitive and meaningful insight.

Despite the remarkable success associated with the monumental double-blind, placebo-controlled COVID-19 vaccine studies, there has been considerable criticism of investigative approaches that examined potential therapeutic strategies to treat or prevent complications of this infection. In fact, the results of an extensive review of the topic document a number of concerning features. The report cites the use of underpowered, inadequately designed and conducted randomized studies; investigators leveraging large but poorly understood databases believed by some to be sufficient to avoid randomization; and, finally, the publication of results in high-impact medical journals by internationally recognized academics of observational data employing dubious or perhaps, nonexistent population-based sources for which stunningly inadequate vetting was employed.1

Execution Gaps Lead to Missed Opportunities

The advent of rapid online coverage of research that has not undergone peer review has enabled widespread reporting of observational research and clinical trial efforts, the stated conclusions of which may be grossly overstated or, frankly, wrong.

Further, consider that in early 2020, COVID-19 was rapidly spreading, affecting both the developed and the developing world. The unfortunate absence of widespread international cooperation in the design and conduct of pragmatic clinical trials to definitively answer simple yet critical questions (eg, quickly defining the benefits or lack thereof for hydroxychloroquine, dexamethasone, and immune serum from survivors of a COVID-19 infection to treat or prevent complications) must be seen as a lost opportunity. However, it should be noted that countries with more centralized public health and research infrastructures mounted impressive controlled clinical trials that helped define clinical efficacy.2,3 Consider just how much could have been rapidly learned if these efforts were conducted on an international rather than a national scale.

Missing the Mark on Informed Consent

A recent report regarding the informed consent process for patients enrolled on COVID-19 vaccine trials adds another element of concern, one that is highly relevant for clinical studies in the cancer domain.4 Considering the highly experimental nature of the initial phase 3 trial efforts of these vaccine products, including lack of solid knowledge of both efficacy and toxicity, one would have anticipated and hoped for considerable clarity in the informed consent document required from all participants. This would include material written at a reading level appropriate for the majority of individuals being asked to participate in this essential societal effort.

Unfortunately, investigators reported that the informed consent forms for 4 of the phase 3 COVID-19 randomized studies examined fell short of what would be considered optimal.4 First, each document was excessively long requiring at least 30 minutes to read at a pace of 240 words a minute. Second, each document exceeded the reasonable standard of ninth-grade reading ability and was overall rated as “difficult.”

Finally, because of the truly experimental nature of these vaccine products, a placebo-controlled study design was essential. In the opinion of this commentator, there can be no objectively valid objection to this decision for the initial study designs. However, considering the fact that, by definition, approximately half of the study population would not receive the active product, it is perhaps more than a little surprising that just 1 of the 4 consent forms specifically stated that “participants with the placebo group might receive vaccine.” Further, the investigators noted, “the reference was oblique and failed to specify timeline or other details.”4

Can the points described here regarding future plans of study participants randomized to the placebo arms possibly be considered appropriate informed consent? Of course, at the time consent was obtained, it was unknown if the various vaccines would be demonstrated to be safe and effective. However, that was always a realistic possibility; otherwise, why conduct the study?

There is a widely held perspective among members of the academic research community that participation in a clinical trial is fundamentally different from clinical care, and the researcher’s obligations to a “research subject” differ from those of a physician providing care to an individual patient. If this argument is accepted, one might conclude that the COVID-19 vaccine trials were specifically designed to answer a scientifically important question rather than provide protection from this dangerous virus for individual participants. Further, carrying the argument to its logical conclusion, investigators would not have an obligation to participants in the placebo arm, assuming the trial had a favorable outcome. Their only responsibility would be to conduct an excellent trial and report the results, which would, hopefully, be relevant to future individuals or patients.

In striking contrast, if we acknowledge both the critically import-ant scientific aims of the study and its potential effect on participants, a plan for future management of individuals randomized to placebo—assuming a positive outcome—is ethically mandated. For example, this might have prospectively included a decision to offer active vaccination to this group once the vaccine received FDA approval for noninvestigative use.

Finally, it must be noted that the experience with informed consent described is potentially relevant for cancer investigative efforts whenever it is deemed appropriate to include a placebo-controlled study arm.

References

  1. Ferreira JP, Epstein M, Zannad F, et al. The decline of the experimental paradigm during the COVID-19 pan-demic: a template for the future. Am J Med. 2021;134(2):166-175. doi:10.1016/j.amjmed.2020.08.021
  2. Horby P, Mafham M, Linsell L, et al; RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospi-talized patients with Covid-19. N Engl J Med. 2020;383(21):2030-2040. doi:10.1056/NEJMoa2022926
  3. Cavalcanti AB, Zampieri FG, Rosa RG, et al; Coalition Covid-19 Brazil I Investigators. Hydroxycloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383(21):2041-2052. doi:10.1056/NEJMoa2019014
  4. Emanuel EJ, Boyle CW. Assessment of length and readability of informed consent documents for COVID-19 vaccine trials. JAMA Netw Open. 2021;4(4):e2110843. doi:10.1001/jamanetworko-pen.2021.10843
Download Issue PDF
Articles in this issue

Benjamin P. Levy, MD
Emerging Therapies Expand Options in Lung Cancer
Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments
Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments
D. Ross Camidge,   MD, PhD
Investigators Explore the Role of VS-6766 and Defactinib in KRAS-Mutant NSCLC
Khalid Matin, MD, FACP
Community-Based Programs Have the Power to Remove Clinical Trial Barriers
Advanced Practice Providers Are Poised to Boost Community Involvement in Clinical Trials
Advanced Practice Providers Are Poised to Boost Community Involvement in Clinical Trials
Persistent Development of WEE1 Pathway Inhibitors Begins to Pay Off
Persistent Development of WEE1 Pathway Inhibitors Begins to Pay Off
Melina Elpi Marmarelis, MD,
Amivantamab Paves a New Treatment Path for Patients With EGFR Exon 20–Mutant NSCLC
Bhavana Pothuri, MD
Dostarlimab Expands Options for dMMR Endometrial Cancer
Maurie Markman, MD, of Cancer Treatment Centers of America
Gaps Persist in Understanding the Fundamentals of Informed Consent
Related Videos
In this fifth episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, underscore the need for additional research evaluating the role of radiofrequency ablation (RFA) and other approaches in pancreatic cancer, and avenues that are ripe for further exploration.
Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.
Tycel Phillips, MD, MPH
Tycel Phillips, MD, MPH
In this fourth episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, discuss what is known about the utilization of endoscopic radiofrequency ablation in nonmetastatic pancreatic adenocarcinoma and the potential for this approach in the paradigm.
Marwan G. Fakih, MD
In this third episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, share how they would best utilize genetic testing results obtained from endoscopic ultrasound–guided biopsies in pancreatic ductal adenocarcinomas.
Daneng Li, MD
Afsaneh Barzi, MD, PhD
Daneng Li, MD
Related Content

City of Hope Receives $100 Million Gift to Create First-of-its-Kind National Integrative Oncology Program

September 27th 2023

FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

June 12th 2023

Generic Drug Shortage of Platinum Agents in Ovarian Cancer Sends Cautionary Signal

September 6th 2023

Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer

April 27th 2023

State of Science Summit- GI Cancers: Chaired by Daneng Li, MD

August 21st 2023

City of Hope Receives $32.3 Million From the California Institute for Regenerative Medicine to Advance Innovative Therapies for Patients

August 18th 2023

City of Hope Receives $100 Million Gift to Create First-of-its-Kind National Integrative Oncology Program

September 27th 2023

FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

June 12th 2023

Generic Drug Shortage of Platinum Agents in Ovarian Cancer Sends Cautionary Signal

September 6th 2023

Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer

April 27th 2023

State of Science Summit- GI Cancers: Chaired by Daneng Li, MD

August 21st 2023

City of Hope Receives $32.3 Million From the California Institute for Regenerative Medicine to Advance Innovative Therapies for Patients

August 18th 2023

City of Hope Receives $100 Million Gift to Create First-of-its-Kind National Integrative Oncology Program

September 27th 2023

FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

June 12th 2023

Generic Drug Shortage of Platinum Agents in Ovarian Cancer Sends Cautionary Signal

September 6th 2023

Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer

April 27th 2023

State of Science Summit- GI Cancers: Chaired by Daneng Li, MD

August 21st 2023

City of Hope Receives $32.3 Million From the California Institute for Regenerative Medicine to Advance Innovative Therapies for Patients

August 18th 2023
Related Content
Advertisement
Edward S. Kim, MD, MBA

City of Hope Receives $100 Million Gift to Create First-of-its-Kind National Integrative Oncology Program

September 27th 2023
Article
Tycel Phillips, MD

FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

June 12th 2023
Podcast
Maurie Markman, MD

Generic Drug Shortage of Platinum Agents in Ovarian Cancer Sends Cautionary Signal

September 6th 2023
Article
Edward S. Kim, MD, MBA

Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer

April 27th 2023
Podcast
State of Science Summit- GI Cancers: Chaired by John L. Hays, MD

State of Science Summit- GI Cancers: Chaired by Daneng Li, MD

August 21st 2023
Article
John D. Carpten, PhD

City of Hope Receives $32.3 Million From the California Institute for Regenerative Medicine to Advance Innovative Therapies for Patients

August 18th 2023
Article

Latest Conference Coverage

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact